FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W137269459> ?p ?o ?g. }

• W137269459 endingPage "37" @default.
• W137269459 startingPage "927" @default.
• W137269459 abstract "It has been proposed that the elimination of excess scar tissue from the body is achieved by specialized killer cells, which are activated by vascular changes in the scar tissue. The malignant tumor is, according to this theory, considered to be a special type of excess scar tissue of fetal or near fetal age, the fetal blood supply of which prevents the activation of those specialized killer cells which were believed to eliminate excess scar tissue. Therefore, it is assumed that if the specialized killer cells of a malignant tumor patient are activated artificially, they would cause malignant tumor regression in vivo. This method of treatment is called autobiotherapy because it utilizes biological products from the patient to treat his own malignant tumor. Preliminary evidence is presented in support of autobiotherapy of malignant tumor disease.The peripheral leucocytes of 27 malignant tumor patients were activated separately by incubation in a serum-free medium containing the respective tumor cells or material. The effect of the injection of the activated leucocytes or their products, termed tumor leucocyte cultures (TLC), was studied in five patients with Kaposi sarcoma, five with carcinoma of the breast, four with carcinoma of the cervix, three with soft tissue sarcoma, two with carcinoma of the lung, two with carcinoma of the maxillary antrium, and a miscellaneous group of six patients. In 52 percent of cases, there was significant tumor regression. Tumor regression was most marked in patients with Kaposi sarcoma, carcinoma of the cervix, pharynx, and pancreas, one patient with a slow growing fibrosarcoma, one patient with a metastatic breast carcinoma, and also in one patient with myelogenous leukemia. However, not all the types of tumor studied responded satisfactorily to autobiotherapy. The reasons for the differences in response to autobiotherapy remain to be determined. Even so, the positive results obtained indicate that autobiotherapy is worthy of further research as an alternative in controlling malignant tumor disease." @default.
• W137269459 created "2016-06-24" @default.
• W137269459 creator A5019990546 @default.
• W137269459 creator A5036254575 @default.
• W137269459 creator A5049795390 @default.
• W137269459 creator A5069359865 @default.
• W137269459 creator A5071435137 @default.
• W137269459 creator A5084988241 @default.
• W137269459 date "1981-10-01" @default.
• W137269459 modified "2023-09-26" @default.
• W137269459 title "Clinical experience with autobiotherapy of malignant tumor disease: a preliminary report." @default.
• W137269459 cites W1981067568 @default.
• W137269459 cites W2006014083 @default.
• W137269459 cites W2042264911 @default.
• W137269459 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2552711" @default.
• W137269459 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6458708" @default.
• W137269459 hasPublicationYear "1981" @default.
• W137269459 type Work @default.
• W137269459 sameAs 137269459 @default.
• W137269459 citedByCount "0" @default.
• W137269459 crossrefType "journal-article" @default.
• W137269459 hasAuthorship W137269459A5019990546 @default.
• W137269459 hasAuthorship W137269459A5036254575 @default.
• W137269459 hasAuthorship W137269459A5049795390 @default.
• W137269459 hasAuthorship W137269459A5069359865 @default.
• W137269459 hasAuthorship W137269459A5071435137 @default.
• W137269459 hasAuthorship W137269459A5084988241 @default.
• W137269459 hasConcept C121608353 @default.
• W137269459 hasConcept C126322002 @default.
• W137269459 hasConcept C142724271 @default.
• W137269459 hasConcept C2776495794 @default.
• W137269459 hasConcept C2777546739 @default.
• W137269459 hasConcept C2777740455 @default.
• W137269459 hasConcept C2778256501 @default.
• W137269459 hasConcept C71924100 @default.
• W137269459 hasConceptScore W137269459C121608353 @default.
• W137269459 hasConceptScore W137269459C126322002 @default.
• W137269459 hasConceptScore W137269459C142724271 @default.
• W137269459 hasConceptScore W137269459C2776495794 @default.
• W137269459 hasConceptScore W137269459C2777546739 @default.
• W137269459 hasConceptScore W137269459C2777740455 @default.
• W137269459 hasConceptScore W137269459C2778256501 @default.
• W137269459 hasConceptScore W137269459C71924100 @default.
• W137269459 hasIssue "10" @default.
• W137269459 hasLocation W1372694591 @default.
• W137269459 hasOpenAccess W137269459 @default.
• W137269459 hasPrimaryLocation W1372694591 @default.
• W137269459 hasRelatedWork W2043617013 @default.
• W137269459 hasRelatedWork W2059373301 @default.
• W137269459 hasRelatedWork W2062623793 @default.
• W137269459 hasRelatedWork W2073462066 @default.
• W137269459 hasRelatedWork W2104090866 @default.
• W137269459 hasRelatedWork W2136356168 @default.
• W137269459 hasRelatedWork W2152089288 @default.
• W137269459 hasRelatedWork W2335750448 @default.
• W137269459 hasRelatedWork W2826710 @default.
• W137269459 hasRelatedWork W88573889 @default.
• W137269459 hasVolume "73" @default.
• W137269459 isParatext "false" @default.
• W137269459 isRetracted "false" @default.
• W137269459 magId "137269459" @default.
• W137269459 workType "article" @default.